More APPI news today, and its important ********* Monday January 11,
12:50 pm Eastern Time
Company Press Release
SOURCE: Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals, Inc. - APPI - Announces the Launching of
their Patent Pending Immune System Supplement 'ACA' in the United States
and International Markets
NEW YORK, Jan. 11 /PRNewswire/ -- Advanced Plant Pharmaceuticals Inc.
(OTC Bulletin Board: APPI - news) announced today that they have
officially launched their patent pending product ACA for retail sales in
the United States and Internationally.
Advanced Plant Pharmaceuticals, Inc. has officially launched the
nutritional version of Abavca. ACA the standardized pharmaceutical grade
nutritional product is targeted for the CFS (Chronic Fatigue Syndrome)
and Immune Supplement market. ACA has been proven to strengthen the
immune system as well as fight the spread of HIV virus. This is an
orally ingested compound that in Pilot studies, Case studies and in
In-vitro studies in the USA and other countries has demonstrated
reversal of glandular swelling, restoration of well-being and associated
weight gain, improvement in response to skin hypersensitivity tests,
increase in the circulating concentration of helper T cells
(CD4-positive cells); associated with this is an improvement in the
CD4/CD8 ratio, with many patients returning to a normal ratio. This type
of response is far different from those experienced by users of any one
drug regimen currently on the market. People who have access to the
expensive new class of drugs called protease inhibitors have seen
similar responses when used in combination with AZT or one of the older
products, but they are not effective for all people. The struggle for
appropriate medication is all the more difficult because scientists and
physicians do not have a clear understanding of which drugs work best
together and whether a patient will prove to be resistant to any of the
drugs in the combination therapy now in use. Also, approximately 100,000
patients have access to these treatments out of an estimated population
of 21.8 million people worldwide who are infected.
The CFS and Immune markets are estimated to be in excess of 6 billion
dollars annually. The total nutritional supplement market is estimated
to be in excess of 23 billion dollars annually in the USA.
Prior distribution agreements signed with Klien Associates of Israel and
Maxwell Associates of England include the distribution of ACA. Both
Companies believe that this product will have immediate market
acceptance. APPI will seek distribution partners who are capable of
gaining access to the areas of the world with the most patients, India,
Southeast Asia and Africa specifically.
ACA will be available on the Company web site located at
advancedplantpharm.com within the week.
On the pharmaceutical side APPI has an approved IND for a Phase I/II
clinical trial for the use of Abavca in the treatment of AIDS. This
trial is anticipated to begin enrolling patients in the 3rd quarter of
1999, following the completion of further regulatory studies, which will
be completed in March. This study should last about 9 months and results
should be submitted to the FDA within one year from its commencement.
The company expects to announce further agreements in the near future.
APPI is a company that develops innovative plant formulations and
technology for clinical application. APPI has met FDA nutritional
specifications for the marketing of its Lo-Chol in the USA, and has
received the first IND from the FDA for a whole plant pharmaceutical
which has potential as an immunomodulater in the treatment of patients
infected with HIV, the virus that causes AIDS.
APPI's Whole Plant Pharmaceutical Grade Process is trade secret and
patent pending. Utilization of the APPI process converts a whole plant
into the best standardized pharmaceutical grade product.
This press release contains forward-looking statements. Such statements
are subject to certain risks and uncertainties and actual results could
differ materially from those expressed in any of the forward-looking
statements.
SOURCE: Advanced Plant Pharmaceuticals, Inc.
------------------------------------------------------------------------
More Quotes and News:Advanced Plant Pharmaceuticals Inc (OTC BB:APPI -
news)Related News Categories: medical/pharmaceutical
------------------------------------------------------------------------
Help
------------------------------------------------------------------------
Copyright © 1999 PRNewswire. All rights reserved. Republication or
redistribution of PRNewswire content is expressly prohibited without the
prior written consent of PRNewswire. PRNewswire shall not be liable for
any errors or delays in the content, or for any actions taken in
reliance thereon.
See our Important Disclaimers and Legal Information |
